Patents by Inventor Hye-Won Kwon

Hye-Won Kwon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ANTIBODY AGAINST CD55 AND USE THEREOF
    Publication number: 20240141061
    Abstract: The present disclosure relates to an antibody binding specifically to CD55 or an antigen-binding fragment thereof; and a composition for preventing, treating and/or diagnosing cancer containing the same. The antibody of the present disclosure may be used as an effective therapeutic composition for various CD55-mediated diseases since it shows high binding ability and inhibitory effect for the CD55 protein which promotes tumor growth by inhibiting the complement immune mechanism. In addition, the antibody of the present disclosure may be usefully used as an effective therapeutic adjuvant that fundamentally removes drug resistance and remarkably improves therapeutic responsiveness in various diseases in which resistance to therapeutic agents with CDC (complement-dependent cytotoxicity) as a mechanism of action has been induced due to overexpression of CD55.
    Type: Application
    Filed: January 12, 2022
    Publication date: May 2, 2024
    Applicants: SG MEDICAL INC, KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, KOREA ATOMIC ENERGY RESEARCH INSTITUTE
    Inventors: Ji Chul LEE, Hye In PARK, Sung-Won MIN, Sung-Won MIN, Hyeong Sun KWON, Jae Cheong LIM, So Hee DOH, Eun Ha CHO, So-Young LEE, Sung Hee JUNG
  • Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
    Patent number: 7834258
    Abstract: The present invention relates to a method producing dimer of chimeric recombinant binding domain-heterogeneous functional group fusion([B-F fusion]2) by using covalent disulfide-bond-bridge connecting the two monomers of chimeric recombinant binding domain-heterogeneous functional group fusion(B-F fusion). The dimer of chimeric recombinant binding domain(B)-heterogeneous functional group(F) fusion was the first to be formed by using covalent disulfide-bond-bridge to connect monomers to have double binding valency of the monomer. It has higher functional efficiency to its targets and the production yield is high by containing said extension peptide chain.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: November 16, 2010
    Inventors: Mu-Hyeon Choe, Seong-Hyeok Choi, Yong-Chan Lee, Hye-Won Kwon, Jae-Seon Won, Mi-Hyun Yu, Jeong-Hwa Song, Yong-Jae Kim
  • Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
    Publication number: 20070009987
    Abstract: The present invention relates to a method producing dimer of chimeric recombinant binding domain-heterogeneous functional group fusion([B-F fusion]2) by using covalent disulfide-bond-bridge connecting the two monomers of chimeric recombinant binding domain-heterogeneous functional group fusion(B-F fusion). The dimer of chimeric recombinant binding domain(B)-heterogeneous functional group(F) fusion was the first to be formed by using covalent disulfide-bond-bridge to connect monomers to have double binding valency of the monomer. It has higher functional efficiency to its targets and the production yield is high by containing said extension peptide chain.
    Type: Application
    Filed: June 30, 2004
    Publication date: January 11, 2007
    Inventors: Mu-Hyeon Choe, Seong-Hyeok Choi, Yong-Chan Lee, Hye-Won Kwon, Jae-Seon Won, Mi-Hyun Yu, Jeong-Hwa Song, Yong-Jae Kim